Beigene Ltd (NASDAQ:BGNE) CMO Amy C. Peterson sold 14,711 shares of Beigene stock in a transaction dated Thursday, November 8th. The stock was sold at an average price of $126.07, for a total transaction of $1,854,615.77. Following the transaction, the chief marketing officer now directly owns 194,569 shares of the company’s stock, valued at $24,529,313.83. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

NASDAQ BGNE opened at $127.00 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 11.47 and a current ratio of 11.57. Beigene Ltd has a 52 week low of $77.54 and a 52 week high of $220.10.

Beigene (NASDAQ:BGNE) last issued its quarterly earnings results on Wednesday, November 7th. The company reported ($2.53) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($2.97) by $0.44. Beigene had a negative net margin of 320.08% and a negative return on equity of 38.44%. The business had revenue of $54.20 million for the quarter, compared to analyst estimates of $47.06 million. During the same quarter in the prior year, the business posted $2.54 EPS. Beigene’s revenue for the quarter was down 75.4% compared to the same quarter last year. On average, research analysts forecast that Beigene Ltd will post -9.75 EPS for the current year.

A number of institutional investors have recently modified their holdings of BGNE. Baker BROS. Advisors LP increased its stake in Beigene by 105.2% during the 2nd quarter. Baker BROS. Advisors LP now owns 11,959,824 shares of the company’s stock valued at $1,838,584,000 after purchasing an additional 6,130,395 shares in the last quarter. Hsbc Holdings PLC increased its stake in Beigene by 1,214.2% during the 3rd quarter. Hsbc Holdings PLC now owns 2,628,418 shares of the company’s stock valued at $452,666,000 after purchasing an additional 2,428,418 shares in the last quarter. Capital Research Global Investors acquired a new position in Beigene during the 3rd quarter valued at approximately $314,859,000. Renaissance Technologies LLC acquired a new position in Beigene during the 2nd quarter valued at approximately $33,377,000. Finally, Pictet Asset Management Ltd. acquired a new position in Beigene during the 3rd quarter valued at approximately $2,213,000. Institutional investors and hedge funds own 77.60% of the company’s stock.

Several equities research analysts have issued reports on BGNE shares. Cowen reissued a “buy” rating on shares of Beigene in a research report on Sunday, October 14th. ValuEngine raised shares of Beigene from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 2nd. BidaskClub raised shares of Beigene from a “hold” rating to a “buy” rating in a research report on Thursday, July 26th. Zacks Investment Research raised shares of Beigene from a “sell” rating to a “hold” rating and set a $124.00 price objective for the company in a research report on Thursday, November 8th. Finally, Leerink Swann started coverage on shares of Beigene in a research report on Monday, September 24th. They issued an “outperform” rating and a $215.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. Beigene has an average rating of “Buy” and a consensus target price of $172.47.

ILLEGAL ACTIVITY WARNING: “Beigene Ltd (BGNE) CMO Amy C. Peterson Sells 14,711 Shares” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/11/16/beigene-ltd-bgne-cmo-amy-c-peterson-sells-14711-shares.html.

About Beigene

BeiGene, Ltd. develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.

Read More: What are the Benefits of Index Funds?

Insider Buying and Selling by Quarter for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.